Novo Nordisk’s oral Semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity

Bagsværd, Denmark, Plainsboro: Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the investigational once-daily…